ACO ame and Location Meritus Health ACO, LLC 11116 Campus Road 3 Link, Suite 3945 Hagerstown, Maryland 21742 ACO Primary Contact Primary Contact ame Andrea Horton, R, BS, ACM-R Primary Contact Phone umber 301-790-8154 Primary Contact Email Address Andrea.Horton@meritushealth.com Organizational Information ACO participants: ACO s ACO in Joint Venture (Enter Y or ) Hagerstown Heart, PA Drs. Waheed, Alencherry, and Iqbal, PA Meritus Urgent Care LLC
ACO governing body: Ross Last ame Member First ame Joseph P. Title/Position Ahmed Kalim Voting Chan Thomas Voting Member/ACO Executive Member's Voting Power Membership Type Voting Member/Chair Cole W. Jason Voting Member Ditto Allen W. Voting Dunnan Ingram Revd. Dr. D. Stuart Bradley S. Voting Member Voting Assistant-Certified Jones Jeffrey Voting Krishnamoorthy Mahesh Voting Vourlekis Jason Voting /ACO Director Simonsen Carolyn Voting Member McGovern Gaye Voting Member 100% Medicare beneficiary representative ACO TI Legal Business ame/dba, if Applicable Drs. Waheed Alencherry and Iqbal PA Hagerstown Heart, PA /A
Key ACO clinical and administrative leadership: Tom Chan ACO Executive Jason Vourlekis, M.D. Director Lauren Klemm Compliance Officer Kathy Lewis Quality Assurance/Improvement Officer Associated committees and committee leadership: Committee ame Committee Leader ame and Position IT, Finance & Administrative Committee Thomas Chan, Chair Quality & Care Transformation Committee Jason Vourlekis, M.D., Chair Compliance Committee Carolyn Simonsen, Chair Types of ACO participants, or combinations of participants, that formed the ACO: ACO professionals in a group practice arrangement etworks of individual practices of ACO professionals Hospital employing ACO professionals Shared Savings and Losses Amount of Shared Savings/Losses /A Shared Savings Distribution /A Quality Performance Results 2016 Quality Performance Results: ACO# Measure ame Rate ACO Mean 1 CAHPS: Getting Timely Care, Appointments, and Information /A 80.51 2 CAHPS: How Well Your Providers Communicate /A 93.01 3 CAHPS: Patients Rating of Provider /A 92.25
4 CAHPS: Access to Specialists /A 83.49 5 CAHPS: Health Promotion and Education /A 60.32 6 CAHPS: Shared Decision Making /A 75.40 7 CAHPS: Health Status/Functional Status /A 72.30 34 CAHPS: Stewardship of Patient Resources /A 26.97 8 Risk Standardized, All Condition Readmission /A 14.70 35 36 37 38 Skilled ursing Facility 30-day All-Cause Readmission measure (SFRM) /A 18.17 All-Cause Unplanned Admissions for Patients with Diabetes /A 53.20 All-Cause Unplanned Admissions for Patients with Heart Failure /A 75.23 All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions /A 59.81 9 10 Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5) Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8) /A 9.27 /A 14.53 11 39 13 14 15 Percent of PCPs who Successfully Meet Meaningful Use Requirements /A 82.72 Documentation of Current Medications in the Record /A 87.54 Falls: Screening for Future Fall Risk /A 64.04 Preventive Care and Screening: Influenza Immunization /A 68.32 Pneumonia Vaccination Status for Older Adults /A 69.21 16 17 18 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow- Up Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention Preventive Care and Screening: Screening for Clinical Depression and Followup Plan /A 74.45 /A 90.98 /A 53.63 19 20 Colorectal Cancer Screening /A 61.52 Breast Cancer Screening /A 67.61
21 Preventive Care and Screening: Screening for High Blood Pressure and Follow- Up Documented /A 76.79 42 27 41 28 30 Statin therapy for the Prevention and Treatment of Cardiovascular Disease /A 77.72 Diabetes Mellitus: Hemoglobin A1c Poor Control /A 18.24 Diabetes: Eye Exam /A 44.94 Hypertension (HT): Controlling High Blood Pressure /A 70.69 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic /A 85.05 31 33 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%) /A 88.67 /A 79.67 Please note, the 40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples. Payment Rule Waivers o, our ACO does not use the SF 3-Day Rule Waiver.